Continuous investment in R&D for our customers and the patients they serve

Thousands of hospitals and laboratories around the globe, along with tens of thousands of patients, rely on the quality and accuracy of our diagnostic solutions every day. This responsibility inspires our R&D leaders and teams worldwide to continuously evolve our systems, reagents, and data management solutions while also innovating new products to expand our impact on diagnostic testing. We refer to this commitment as Powering Patient Care.

In 2024, our global R&D departments grew to over 900 employees, all dedicated to advancing our programs, products, and talent. We invested €179 million in R&D, a significant investment that demonstrates our commitment to innovation and ongoing quality improvement.

Guided by a new and ambitious strategic plan, our energy and talent are focused on key programs and development activities across our systems, reagents, and digital solutions.

Our R&D teams across our business lines: Hemostasis, Acute Care, Transfusion, Autoimmunity, and Transplant, are dedicated to creating solutions that advance patient care and improve patient outcomes. As the company grows, our R&D teams collaborate more effectively, further strengthening our cohesive R&D organization and supporting our One Company, One Team approach.

Our pipeline is filled with exciting innovations that will positively influence both our short-term and long-term growth and success. These innovations are designed to deliver clinically impactful solutions that enhance the experience of our customers.